SG Americas Securities LLC lifted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 74.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,008 shares of the biopharmaceutical company’s stock after buying an additional 2,991 shares during the quarter. SG Americas Securities LLC’s holdings in Esperion Therapeutics were worth $324,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. BB Biotech AG grew its position in shares of Esperion Therapeutics by 7.6% during the first quarter. BB Biotech AG now owns 1,408,542 shares of the biopharmaceutical company’s stock worth $49,736,000 after buying an additional 100,000 shares in the last quarter. FMR LLC grew its position in shares of Esperion Therapeutics by 70.8% during the first quarter. FMR LLC now owns 1,308,588 shares of the biopharmaceutical company’s stock worth $46,206,000 after buying an additional 542,579 shares in the last quarter. Boxer Capital LLC acquired a new position in shares of Esperion Therapeutics during the first quarter worth about $45,020,000. Credit Suisse AG grew its position in shares of Esperion Therapeutics by 26.4% during the first quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock worth $31,030,000 after buying an additional 183,440 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its position in shares of Esperion Therapeutics by 561.6% during the first quarter. Pinnacle Associates Ltd. now owns 770,618 shares of the biopharmaceutical company’s stock worth $27,211,000 after buying an additional 654,138 shares in the last quarter. 83.33% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently commented on ESPR shares. ValuEngine raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Citigroup Inc. reissued a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Jefferies Group LLC started coverage on Esperion Therapeutics in a research report on Monday, July 10th. They set a “hold” rating and a $55.00 price objective for the company. Stifel Nicolaus reissued a “buy” rating and set a $60.00 price objective (up from $45.00) on shares of Esperion Therapeutics in a research report on Monday, June 26th. Finally, Deutsche Bank AG started coverage on Esperion Therapeutics in a research report on Friday, June 23rd. They set a “buy” rating and a $48.00 price objective for the company. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and an average target price of $52.54.
Esperion Therapeutics, Inc. (NASDAQ ESPR) opened at 50.69 on Friday. The company has a 50-day moving average price of $47.98 and a 200-day moving average price of $40.23. Esperion Therapeutics, Inc. has a one year low of $9.40 and a one year high of $57.38. The firm’s market capitalization is $1.15 billion.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.25). During the same period in the prior year, the firm posted ($0.62) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/15/sg-americas-securities-llc-has-324000-stake-in-esperion-therapeutics-inc-espr.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.